BRAINEVER

Servier Builds Rare Neurology Pipeline from the Ground Up Under New R&D Leadership

- Nitza Thomasson joined Servier in March 2025 as Executive Director and Global Head of R&D Neurology to build the company's rare neurology therapeutic area from scratch. - Servier currently has three neurology drugs in its pipeline, targeting rare refractory epilepsies, movement disorders, neuromuscular disorders, and other conditions. - The company recently strengthened its portfolio through the acquisition of Edgewise Therapeutics' neuromuscular dystrophy pipeline. - Thomasson emphasizes that success in rare neurology requires embracing scientific uncertainty, adapting approaches to each disease, and building a team culture grounded in trust and high expectations.